| AstraZeneca plans new pivotal lung cancer trial with Incyte | | | LONDON (Reuters) - AstraZeneca is stepping up its bet on immunotherapy combination treatments to fight lung cancer by signing a deal with Incyte under which the two companies will start a final-stage Phase III clinical trial next year. |
| |
| Aid groups struggle to improve dire conditions for Rohingya refugees | | | (Reuters Health) - More than a half-million Rohingya people have fled the latest wave of violence in Myanmar for refugee camps in Bangladesh, and most lack clean water, latrine facilities or even shelter from the elements, according to a Medicins Sans Frontiers physician based there. |
| |
| Obamacare benchmark premiums up 37 percent in 2018 after subsidy cut-off | | | NEW YORK (Reuters) - The average monthly premium for benchmark Obamacare insurance plans will surge around 37 percent in 2018, the U.S. Department of Health and Human Services said on Monday, fueled by the Trump administration's suspension of billions of dollars in subsidy payments to health insurers. |
| |
| Cancer-drug setback sends Merck shares down again | | | NEW YORK (Reuters) - A setback for Merck & Co's key cancer drug sent the drugmaker's stock swooning on Monday for a second straight session, putting the shares on track for their biggest two-day decline in more than eight years. |
| |
| Chemed to pay $75 million over false claims lawsuit: Justice Dept | | | WASHINGTON (Reuters) - Chemed Corp and subsidiaries including Vitas Hospice Services LLC and Vitas Healthcare Corp have agreed to pay $75 million to resolve a federal lawsuit alleging false claims for hospice services to Medicare, the U.S. Justice Department said on Monday. |
| |
| | |
